The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists

The design and profile of a series of adamantyl-containing long acting β2-adrenoreceptor agonists are described. An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacology profile when assessed using a guinea pig trachea tissue model. A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clinical trials.

The design and profile of a series of adamantyl-containing long acting β2-adrenoreceptor agonists are described. An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacology profile when assessed using a guinea pig trachea tissue model. A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clinical trials.Figure optionsDownload as PowerPoint slide